Date | Title | Description | |
---|---|---|---|
31 Jul 2024 | On P&L | The Company releases the press release related to the first half 2024 financial results | Download |
31 Jul 2024 | On P&L | The Company releases the first half 2024 financial results presentation | Download |
26 Jun 2024 | On corporate transactions | ROVI notes the recent press speculation and informs about the assessment of potential strategic alternatives | Download |
24 Jun 2024 | On business and financial situation | ROVI publishes the press release in relation to information and guidance on its strategic plan for expansion and growth | Download |
08 May 2024 | On P&L | The Company releases the first three months 2024 financial results presentation | Download |
Pages
Date | Title | Description | |
---|---|---|---|
28 Feb 2022 | Share buy-back , stabilisation and treasury stock programme | Share Buyback Program: transactions conducted between 23 February 2022 and 25 February 2022 | Download |
23 Feb 2022 | Annual Report regarding remuneration of the members of the Board of Directors | ROVI releases the 2021 annual report regarding remuneration of the members of the Board of Directors | Download |
23 Feb 2022 | Annual Corporate Governance Report | ROVI releases the 2021 Annual Corporate Governance Report | Download |
21 Feb 2022 | Share buy-back , stabilisation and treasury stock programme | Share Buyback Program: transactions conducted between 14 February 2022 and 21 February 2022 | Download |
15 Feb 2022 | On business and financial situation | ROVI has announced that the European Commission has authorised the marketing of Okedi® for the treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone. | Download |
Pages
Date | Title | Description | |
---|---|---|---|
07 Nov 2019 | Information on P&L | ROVI releases the first nine months 2019 results presentation | Download |
03 Oct 2019 | Liquidity contracts and specialists | Liquidity contract: transactions conducted in the third quarter of 2019 | Download |
05 Sep 2019 | Others on business performance and financial information | The Company informs about the construction of a second heparin plant in Granada | Download |
30 Jul 2019 | Information on P&L | ROVI releases the first half 2019 results presentation | Download |
30 Jul 2019 | Information on P&L | ROVI releases the press release related to the first half 2019 financial results | Download |